Of the remaining 16 involved_in associations involving DRD1 three of the diseases represent known off-label indications for Propranolol being: Bipolar disorders; Schizophrenia, Alcoholism and as a non-stimulant treatment for ADHD (Gobbo & Louzã, 2014). This evidence concerns the gene DRD1 and attention deficit-hyperactivity disorder.